Study summary: This study aims to assess the feasibility of implementing surveillance protocols among high-risk individuals with a familial and/or genetic predisposition to pancreatic cancer.
Status: OPEN - Recruiting
Sponsor: Epworth HealthCare
Diagnosis or condition: Individuals considered at high-risk of developing pancreatic cancer
  • Key inclusion criteria
    1. Aged ≥ 18 and ≤ 90 years old
    2. Without medical history of pancreatic cancer
    3. Meet ANY of the following criteria:
      1. Familial Pancreatic Cancer Group 1
        • ≥2 relatives with pancreatic cancer, on same side of family, where the 2 affected are first degree related to each other
          AND
        • ≥ 1 affected is first degree related to participant
          AND
        • ≥50 years of age, or 10 years younger than earliest pancreatic cancer in family at time of diagnosis.
      2. Familial Pancreatic Cancer Group 2
        • ≥2 affected first degree relatives with pancreatic cancer
          AND
        • ≥50 years of age, or 10 years younger than earliest pancreatic cancer in family.
      3. Pathogenic Variants
        • BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, or EPCAM pathogenic or likely pathogenic variant
          AND
        • 1 first or second degree relative with pancreatic cancer
          AND
        • ≥50 years of age, or 10 years younger than earliest pancreatic cancer in family.
      4. Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM)
        • Familial Atypical Multiple Mole Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant
          AND
        • ≥40 years of age.
      5. Peutz-Jeghers Syndrome
        • Peutz-Jeghers syndrome with STK11 pathogenic or likely pathogenic variant
          AND
        • ≥35 years of age.
      6. Hereditary Pancreatitis
        • Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant
          AND
        • History of pancreatitis
          AND
        • ≥40 years of age, or 20 years after onset of pancreatitis (whichever is earlier).
  • Key exclusion criteria
    • Individuals who are considered clinically unfit to undergo surveillance by EUS or MRI.
    • Individuals who have been previously diagnosed with or treated for pancreatic cancer.

APRISE

Locations: Epworth Richmond

Epworth PI: A/Prof Andrew Metz

Jreissati Pancreatic Centre at Epworth 

Access this Research Study

Healthcare professionals


Refer your patient

General enquiries

Please contact us for more information on 03 9426 8880 or email [email protected]


Back to all Clinical Trials and Research Studies